Anand joined Sofinnova in 2007 as a Principal. In 2014, he was promoted to General Partner. He focuses on working with entrepreneurs to build drug development companies that have the power to improve the lives of patients. Anand represents Sofinnova on the boards of Aclaris (ACRS), Amplyx, Merus (MRUS), and Spark Therapeutics (ONCE). Prior to joining Sofinnova, Anand worked at JP Morgan Partners in private equity and venture capital. Before joining the venture community, he was a consultant for McKinsey & Company’s healthcare practice, advising large pharmaceutical and biotech companies on core strategic issues.
Anand received his M.D. from Columbia University’s College of Physicians and Surgeons. He was an Echols Scholar and conducted National Institute of Health sponsored research on the outcomes, mechanisms, and pre-clinical development of therapeutic agents for stroke. He graduated Phi Beta Kappa from the University of Virginia with a B.A. in Political Theory through the Government Honors program. While in college, he spent three years as a firefighter for the Seminole Trail Fire Department.